Commercialization of ASONEP for the Treatment of Cancer

ASONEP 用于癌症治疗的商业化

• 批准号: 8078957
• 负责人: Roger A Sabbadini
• 金额: $ 100万
• 依托单位: LPATH THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-07 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8078957
• 关键词: Angiogenesis Inhibitors; Animals; Antibodies; Antineoplastic Agents; Biological Markers; Cancer Etiology; Cancer Patient; Cancer Therapy Evaluation Program; Cause of Death; Cessation of life; Clinic; Clinical; Clinical Trials; Collaborations; Complement; Development; Development Plans; Disease; Distant; Drug Formulations; Drug Kinetics; Enzymes; Funding; Future; Genomics; Government; Grant; Growth; Growth Factor; Human; Lipids; Malignant Neoplasms; Marketing; Mediating; Monoclonal Antibodies; Multivariate Analysis; Mus; Oncogenes; Outcome; Patient Selection; Patients; Pharmacologic Substance; Phase; Phase I Clinical Trials; Plasma; Production; Progress Reports; Proteomics; Research; Research Design; Resistance; Resistance development; SPHK1 enzyme; Safety; Sampling; Series; Signal Transduction; Site; Small Business Innovation Research Grant; Sphingolipids; Surrogate Markers; System; Testing; Therapeutic; Therapeutic Agents; Tissues; Transgenic Mice; Up-Regulation; Validation; Xenograft procedure; anticancer research; base; cancer cell; cancer diagnosis; cancer therapy; cancer type; chemotherapy; clinical efficacy; commercialization; cytotoxic; design; efficacy trial; extracellular; humanized monoclonal antibodies; mouse model; nonhuman primate; novel; oncology; overexpression; phase 1 study; pre-clinical; preclinical efficacy; preclinical study; programs; research and development; safety study; sphingosine 1-phosphate; standard care; success; tumor; tumor growth; tumor progression; tumorigenic

DESCRIPTION (provided by applicant): Lpath Inc. has developed a novel cancer therapeutic agent, ASONEPTM, a humanized monoclonal antibody, which neutralizes the tumorigenic and angiogenic growth factor, sphingosine-1-phosphate (S1P). S1P is an unusual target as it is a bioactive lipid. Thus ASONEP potentially represents a first-in-class anti-cancer agent. ASONEP is currently in Phase 1 trials for cancer. For this grant, we are requesting matching funds for clinical development and commercialization of ASONEP. Lpath has performed a comprehensive series of pre-clinical efficacy and pharmacokinetic studies to confirm the potential anti-cancer utility of the anti-S1P antibody. The neutralization of extracellular S1P mediated by the anti-S1P mAb could result in a marked decrease in cancer progression in humans as a result of inhibition of tumor proliferation and the growing vasculature needed to support tumor growth. Furthermore, recent research suggests that many angiogenesis inhibitors may also act as anti-invasive and anti-metastatic compounds which could also mitigate the spread of cancer to sites distant from the initial tumor. Up-regulation of the oncogene, sphingosine kinase 1 (sphk1) and the resulting release of S1P into the tumor microenvironment represents an important mechanism by which cancer cells acquire resistance to treatment as the cancer progresses. We hypothesize that overexpression of the SphK1 enzyme and the increased production and release of its product, S1P, could be responsible for resistance to cytotoxics and other treatments in a wide variety of cancer lineages. Using S1P as a biomarker and SphK1 as a surrogate marker, we believe that it may be possible to identify patients whose resistance can be attributed to an up-regulation of the S1P system. We will investigate whether sensitivity to therapy can be promoted in these patients with ASONEP in combination with standard treatments against which the patient has developed resistance as a consequence of S1P up-regulation. In moving towards commercialization, we will conduct one Phase 1b safety trial and one Phase 2a clinical trial in selected cancer types based on potential efficacy in the Phase 1 study and/or those demonstrating a promise of efficacy from preclinical and clinical biomarker studies. As requested by the FDA, a 13-week safety study in nonhuman primates will be completed prior to initiation of these Phase 2a studies. In support of the Phase 1b and 2a studies, we will also conduct a biomarker study designed to provide validation of sphingolipid-specific biomarkers (i.e. plasma S1P) and surrogate markers (e.g., tissue SphK1) to help aid in the selection of patients and cancer disease types where resistance to standard treatment may be attributed to an up-regulation of the S1P signaling system. Multivariate analysis will also be performed to assess the correlation of S1P-specific biomarkers/surrogate markers with other relevant signals that will be obtained from genomic and proteomic arrays of patient samples. This aim will be used to support future Phase 0 biomarker studies not supported by the SBIR Bridge grant. As an additional specific aim of the project, we will conduct preclinical studies using animal xenografts and transgenic mouse models intending to demonstrate that acquired resistance to cytotoxics and other treatments could be reversed by anti-S1P treatment. Efficacy studies will determine whether the anti-S1P mAb treatment can re-establish sensitivity to treatment. These studies will be used in conjunction with the biomarker/surrogate marker studies to select primary indications for future Phase 2 efficacy trials.

描述（申请人提供）：Lpath Inc.开发了一种新型癌症治疗剂ASONEPTM，一种人源化单克隆抗体，可中和致瘤和血管生成生长因子1-磷酸鞘氨醇（S1P）。 S1P 是一个不寻常的目标，因为它是一种生物活性脂质。因此，ASONEP 可能代表一种一流的抗癌药物。 ASONEP 目前正在进行癌症一期试验。对于这笔赠款，我们正在请求配套资金用于 ASONEP 的临床开发和商业化。 Lpath 进行了一系列全面的临床前功效和药代动力学研究，以证实抗 S1P 抗体的潜在抗癌效用。抗 S1P mAb 介导的细胞外 S1P 的中和可显着减缓人类癌症进展，因为抑制了肿瘤增殖和支持肿瘤生长所需的血管系统的生长。此外，最近的研究表明，许多血管生成抑制剂也可能充当抗侵袭和抗转移化合物，这也可以减轻癌症向远离初始肿瘤的部位扩散。 癌基因鞘氨醇激酶 1 (sphk1) 的上调以及由此导致的 S1P 释放到肿瘤微环境中，是癌细胞随着癌症进展而获得治疗耐药性的重要机制。我们假设 SphK1 酶的过度表达及其产物 S1P 的产生和释放增加可能是多种癌症谱系对细胞毒素和其他治疗产生耐药性的原因。使用S1P作为生物标志物和SphK1作为替代标志物，我们相信有可能识别出其耐药性可归因于S1P系统上调的患者。我们将研究是否可以提高这些 ASONEP 患者对治疗的敏感性，并结合患者因 S1P 上调而产生耐药性的标准治疗。 在迈向商业化的过程中，我们将根据 1 期研究的潜在疗效和/或临床前和临床生物标志物研究证明的疗效前景，对选定的癌症类型进行一项 1b 期安全试验和一项 2a 期临床试验。根据 FDA 的要求，在启动这些 2a 期研究之前，将在非人类灵长类动物中完成为期 13 周的安全性研究。为了支持 1b 期和 2a 期研究，我们还将进行一项生物标志物研究，旨在验证鞘脂特异性生物标志物（即血浆 S1P）和替代标志物（例如组织 SphK1），以帮助选择患者和癌症对标准治疗的抵抗可能归因于 S1P 信号系统的上调的疾病类型。还将进行多变量分析，以评估 S1P 特异性生物标志物/替代标志物与从患者样本的基因组和蛋白质组阵列中获得的其他相关信号的相关性。这一目标将用于支持未来不受 SBIR Bridge 拨款支持的 0 期生物标志物研究。作为该项目的另一个具体目标，我们将使用动物异种移植物和转基因小鼠模型进行临床前研究，旨在证明抗 S1P 治疗可以逆转对细胞毒素和其他治疗的获得性耐药。功效研究将确定抗 S1P mAb 治疗是否可以重新建立对治疗的敏感性。这些研究将与生物标志物/替代标志物研究结合使用，为未来的 2 期疗效试验选择主要适应症。

项目成果

Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer.

• DOI: 10.18632/oncotarget.3144
• 发表时间: 2015-05-30
• 期刊: Oncotarget
• 作者: Ader I;Gstalder C;Bouquerel P;Golzio M;Andrieu G;Zalvidea S;Richard S;Sabbadini RA;Malavaud B;Cuvillier O
• 通讯作者: Cuvillier O